(CBS) — Their dog was near death from a brain tumor, but a new treatment – a pill for cancer – has extended her life. Now, doctors are studying if this same treatment could also help human patients.
CBS 2’s Marissa Bailey reports.READ MORE: Mars Wrigley Says It Will Move Most Operations Out Of Its Plant On Chicago's West Side Over Next 2 Years
Something terrifying happened this past summer with Albert and Genevieve Pierceall’s rescue pup, Abby.
“She looked like she was going to yawn or something and kind of stretch her legs out, and I realized that she had completely locked up and started convulsing,” Albert Pierecall says.
An MRI revealed brain cancer.
“They told us that it was probably just a couple of months that she had,” recalls Genevieve Pierceall.
The only option? An experimental drug called PAC-1.
The drug has minimal side effects and no guarantee it would work. But it did.
There was an 8 percent reduction in the size of the tumor, Albert Pierceall says. The reduction came after a couple of months of taking the drug.
A follow-up MRI, four months after starting therapy, showed no tumor growth.
Paul Hergenrother, a chemistry professor, discovered PAC-1 10 years ago in his University of Illinois lab.READ MORE: Chicago White Sox Plan To Take Action After CBS 2 Investigators Expose Parking Scam Outside Sports Venues: Fans Getting Ripped Off By Conmen, Then Hit With Parking Tickets
“We have seen positive results especially in combination with other widely used cancer drugs,” he says.
Hergenrother works with veterinary oncologist Dr. Timothy Fan using the pill in dogs, including Abby.
In another dog treated with the drug, they achieved a tumor reduction of nearly 50 percent.
The doctors are happy with results so far but say it’s important to keep realistic expectations.
“There still needs to be some large-scale clinical trials done in companion animals for veterinary oncologists or veterinarians to gain a lot of confidence that this really changes the game,” Dr. Fan says.
PAC-1 has shown promising results in animals, but it’s also part of a human clinical study with promising results at the University of Illinois at Chicago.
“We are still in the Phase 1 trial,” medical oncologist Oano Danciu says.
Twenty people are a part of the study that started almost two years ago.
“It is fair to say so far so good,” Danciu says.
It’s at least five to eight years away from being widely available to human patients. The Piercealls are just glad it worked for Abby.MORE NEWS: Three Men Shot At Stadium Sports Club In Rolling Meadows
“If we get six more months that will be amazing,” Genevieve Pierceall says.